Kessler A T, Kourtis A P
Department of Medicine, Northside-Cherokee Hospital, Atlanta, GA 30013, USA.
Infection. 2007 Jun;35(4):271-4. doi: 10.1007/s15010-007-6211-z. Epub 2007 Jul 23.
Methicillin-resistant Staphylococcus aureus (MRSA) is increasing in prevalence both in nosocomial and in community settings. Treatment of such infections, particularly in the central nervous system (CNS), is problematic, as available options are limited. Linezolid is a new antibiotic with activity against Gram-positive cocci, including MRSA, and has good penetration into the cerebrospinal fluid. To our knowledge, there are only three case reports of successful treatment of CNS infections caused by MRSA with linezolid; we report herein a fourth such case. Clinical trials to address the role of linezolid in CNS infections are urgently needed.
耐甲氧西林金黄色葡萄球菌（MRSA）在医院和社区环境中的患病率都在上升。此类感染的治疗，尤其是中枢神经系统（CNS）感染的治疗存在问题，因为可用的治疗选择有限。利奈唑胺是一种新型抗生素，对革兰氏阳性球菌包括MRSA有活性，并且能很好地穿透脑脊液。据我们所知，仅有3例使用利奈唑胺成功治疗由MRSA引起的中枢神经系统感染的病例报告；我们在此报告第4例此类病例。迫切需要进行临床试验以明确利奈唑胺在中枢神经系统感染中的作用。
Zotero 插件